All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?
Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?
Stein discusses the results of a study evaluating the efficacy of enasidenib monotherapy with a response-adapted addition of azacitidine in older patients with newly diagnosed IDH2-mutated AML.
Sharing advances in the treatment and management of AML
The 21st of April marks an important day in the AML calendar, a day when the AML community unites to mark AML World Awareness Day and raise awareness of the advances in AML.
ASH 2017 | Emerging molecularly targeted therapies in AML: focus on IDH inhibitors
IDH mutations occur in approximately 20% of AML patients, with the prevalence increasing with patient age
Subscribe to get the best content related to AML delivered to your inbox